Goldman Sachs initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $27 price target representing 51% upside. The company can continue to see volume growth within the therapy selection offering, the analyst tells investors in a research note. Goldman also believes Caris has potential to unlock additional addressable market opportunities through upcoming launches in its pipeline.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences announces finalized Achieve 1 Study results
- Caris Life Sciences announces publication of study on GPSai algorithm
- Caris Life Sciences introduces new Caris AI Insights
- Caris Life Sciences price target lowered to $22 from $30 at Canaccord
- Caris Life Sciences Signals Strong Growth and Ambition